{"groups":[{"description":"Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks","id":"FG000","title":"Denosumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"progression of disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}